Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2009-07-08

Clinical Trial Update: Study Of SU011248 (Sunitinib) Given In A Continuous Daily Regimen In Patients With Advanced Renal Cell Cancer [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating continuous daily dosing of sunitinib (SU011248) in patients with advanced renal cell carcinoma; results have been posted following co…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sutent (sunitinib)

Snippet

Sponsor: Pfizer | Conditions: Carcinoma, Renal Cell Metastasis | Phase 2 | Status: COMPLETED | Results posted: 2009-07-08